Cargando…

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison

Introduction: Secondary hyperparathyroidism (sHPT) is a common hormonal complication of chronic kidney disease. There are several therapeutic options for sHPT management aiming at calcium-phosphorus balance normalization and decrease of parathormone secretion. Objectives: The aim of this retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zawierucha, Jacek, Malyszko, Jolanta, Malyszko, Jacek S., Prystacki, Tomasz, Marcinkowski, Wojciech P., Dryl-Rydzynska, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371033/ https://www.ncbi.nlm.nih.gov/pubmed/30804890 http://dx.doi.org/10.3389/fendo.2019.00040

Ejemplares similares

The prevalence of hepatitis C and B among patients on hemodialysis and on renal transplantation waiting list in Poland has significantly decreased during the last 10 years
por: Malyszko, Jolanta, et al.
Publicado: (2018)

Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient
por: Malyszko, Jolanta, et al.
Publicado: (2016)

Lack or insufficient predialysis nephrology care worsens the outcomes in dialyzed patients – call for action
por: Milkowski, Andrzej, et al.
Publicado: (2022)

How COVID-19 Outbreak Influenced Transplantation in Poland
por: Zawierucha, Jacek, et al.
Publicado: (2023)

Medical waste management – how industry can help us to protect environment and money?
por: Żebrowski, Paweł, et al.
Publicado: (2020)

Green Dialysis: Let Us Talk about Dialysis Fluid
por: Zawierucha, Jacek, et al.
Publicado: (2023)

Apparently Resistant Hypertension in Polish Hemodialyzed Population: Prevalence and Risk Factors
por: Symonides, Bartosz, et al.
Publicado: (2023)

Vaccination and COVID-19 in Polish Dialysis Patients: Results from the European Clinical Dialysis Database
por: Marcinkowski, Wojciech, et al.
Publicado: (2022)

Eco-dialysis: fashion or necessity
por: Wieliczko, Monika, et al.
Publicado: (2020)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Effects of dialyzer reuse on dialysis adequacy, anemia control, erythropoieting-stimulating agents use and phosphate level
por: Malyszko, Jolanta, et al.
Publicado: (2016)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review
por: Li, Xiaosong, et al.
Publicado: (2023)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Main Barriers to the Introduction of a Home Haemodialysis Programme in Poland: A Review of the Challenges for Implementation and Criteria for a Successful Programme
por: Kendzia, Dana, et al.
Publicado: (2022)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
por: Jeong, Sohyun, et al.
Publicado: (2016)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?
por: Małyszko, Jolanta, et al.
Publicado: (2017)

Hypertension in malignancy–an underappreciated problem
por: Małyszko, Jolanta, et al.
Publicado: (2018)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Serum neutrophil gelatinase-associated lipocalin as a marker of kidney function in pregnancy – useful or doubtful?
por: Małyszko, Jacek S., et al.
Publicado: (2010)

Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant
por: Malyszko, Jolanta, et al.
Publicado: (2017)

Current Status of Renal Anemia Pharmacotherapy—What Can We Offer Today
por: Borawski, Bartłomiej, et al.
Publicado: (2021)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients
por: Malyszko, Jolanta, et al.
Publicado: (2010)

Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients
por: Koc-Zorawska, Ewa, et al.
Publicado: (2012)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vc214cssm9od682mgf03oee5ti